Cyprotex plc Sets 52-Week High; Strong Momentum for Holders

 Cyprotex plc Sets 52 Week High; Strong Momentum for Holders

The stock of Cyprotex plc (LON:CRX) hit a new 52-week high and has GBX 168.01 target or 6.00% above today’s GBX 158.50 share price. The 5 months bullish chart indicates low risk for the GBX 35.79 million company. The 1-year high was reported on Nov, 22 by Barchart.com. If the GBX 168.01 price target is reached, the company will be worth GBX 2.15M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock decreased 0.47% or GBX 0.75 on November 22, hitting GBX 158.5. About 9,800 shares traded hands. Cyprotex plc (LON:CRX) has risen 65.03% since April 22, 2016 and is uptrending. It has outperformed by 60.47% the S&P500.

More important recent Cyprotex plc (LON:CRX) news were published by: Businesswire.com which released: “Evotec Announces Its Intent to Acquire Cyprotex Plc” on October 26, 2016, also Uk.Finance.Yahoo.com published article titled: “-LSE Ticker: P25RZ1/ISIN: GB00BP25RZ14”, Finance.Yahoo.com published: “Evotec AG Announces Its Intent to Acquire Cyprotex PLC” on October 26, 2016. More interesting news about Cyprotex plc (LON:CRX) was released by: Bizjournals.com and their article: “Cytocentrics CEO: San Antonio to get big boost from new deal” with publication date: February 10, 2016.

Cyprotex PLC is a holding company. The Firm and its subsidiaries are engaged in the provision of in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetic (PK) information to the pharmaceutical and biotechnology industries. The company has a market cap of 35.79 million GBP. It offers a range of different services in the areas of ADME-PK, in vitro toxicology, biosciences, in silico prediction, in vitro skin and ocular testing, endocrine disruption and physicochemical profiling. It currently has negative earnings. The Company’s in vitro ADME and drug metabolism and pharmacokinetics (DMPK) services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment